MRNA Stock Recent News
MRNA LATEST HEADLINES
Prior to the COVID pandemic, the biopharma outfit wasn't a particularly well-known name. Being one of the few pharma companies that could quickly come up with a vaccine, however, catapulted its stock.
Moderna stock broke out of a cup-with-handle base after its first-quarter sales and earnings report. Is MRNA stock a buy right now?
Calpers slashed investments in Verizon, Disney, and Peloton stock, and doubled down on Moderna shares in the first quarter.
Pharma stocks and massive potential go hand in hand. With devastating diseases like cancer, diabetes and heart disease still far from finding a cure, drugs that treat these conditions often command exorbitant prices.
Investors and analysts broadly expected the biotech's results to wither in the first quarter, and they were right. Still, it did better than many anticipated.
Moderna's (MRNA) adjusted EPS came in at -$3.07 versus an estimated -$3.59 and revenue came in at $167.00M versus an estimated $124.74M. CFO Jamey Mock joins Oliver Renick to discuss Moderna's 1Q earnings and the outlook for the company.
Shares of pharmaceutical company Moderna (MRNA) are on the rise despite first quarter losses. Moderna CEO Stéphane Bancel tells Yahoo Finance Senior Reporter Anjalee Khemlani that the company is busy developing updated coronavirus vaccines for the 2024-2025 season and recently announced an expansion into the Brazilian market.
Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.
Here are two biotech stocks to watch after their recent earnings report.
Moderna (MRNA) came out with a quarterly loss of $3.07 per share versus the Zacks Consensus Estimate of a loss of $3.59. This compares to earnings of $0.19 per share a year ago.